Clinical Research Directory
Browse clinical research sites, groups, and studies.
Bismuth Subsalicylate's Role in the Prevention of Travelers' Diarrhea
Sponsor: Centers for Disease Control and Prevention
Summary
The purpose of this study is to determine if the use of prophylactic bismuth subsalicylate (BSS) has an effect on the acquisition of travelers' diarrhea (TD) or antimicrobial resistance (AMR) genes in fecal samples among international travelers who departed from the United States to South East Asia, South Central Asia, or Africa. Our hypotheses will be tested using a double-blinded, placebo controlled randomized clinical trial with participants from a pre-travel health clinic in the United States.
Official title: Bismuth Subsalicylate's Role in the Prevention of Travelers' Diarrhea and Impact on Acquisition of Gut Antimicrobial Resistance Genes
Key Details
Gender
All
Age Range
18 Years - 69 Years
Study Type
INTERVENTIONAL
Enrollment
482
Start Date
2018-05-20
Completion Date
2026-04-29
Last Updated
2026-05-22
Healthy Volunteers
Yes
Interventions
Bismuth subsalicylate
Bismuth subsalicylate administered orally as tablets (4 tablets twice daily; total daily dose approximately 2.1 g) beginning prior to arrival at the travel destination and continued throughout the duration of travel (up to 21 days).
Placebo
Matching oral placebo tablets administered twice daily, identical in appearance, taste, and packaging to bismuth subsalicylate, given for the duration of travel (up to 21 days).
Locations (1)
Marina Rogova
New York, New York, United States